At the same, real‐world evidence on the protracted adjunctive use (≥ 1 year) of GLP‐1RAs in T1D patients with a mean age of 55 years, BMI of 34 kg/m2, and unsatisfactory glucose control (all had HbA1c levels > 7%; mean value: 8.5%) revealed a remarkable weight (−8.4% from baseline) and HbA1c (−0.5% from baseline) decrease and insulin sensitivity amelioration, without increasing the risk of diabetic ketoacidosis, and new onset or progression of retinopathy in those individuals who achieved rapid improvement of glucose control [60]. This evidence concerns the gene INS and type 1 diabetes mellitus.